"Efficacy of olanzapine in acute bipolar mania: A double-blind, placebo-controlled study": Comment.

Reports an error in the original article by M. Tohen et al ( Archives General Psychiatry , 2000, Vol 47, 841-849). In the article M. Tohen et al attribute to W. Brown the suggestion that the benefits of placebo have similarities with the benefits of psychotherapy, when it really should have been attributed to J. D. Frank. (The following abstract of this article originally appeared in record [rid]2000-02503-004[/rid]) Conducted a double-blind, placebo-controlled 28 day study to evaluate the efficacy and safety of olanzapine in the treatment of acute bipolar mania. 115 patients (aged 18-70 yrs) with bipolar disorder, manic or mixed, with or without psychotic features participated in this study. The severity of illness and psychopathologic features were measured by the Young-Mania Rating Scale (Y-MRS), Hamilton Psychiatric Rating Scale for Depression--21 Item, Clinical Global Impressions--Bipolar Version of Severity of Illness, and the Positive and Negative Syndrome Scale. Safety was monitored by assessing adverse events. The olanzapine group experienced a 6.65-point greater mean improvement in Y-MRS total score compared with the placebo group. The only treatment-emergent event with a significant more frequent occurrence in the olanzapine group was somnolence. Results suggest that... (PsycInfo Database Record (c) 2021 APA, all rights reserved)